Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)
Due to the differences in selecting target antigens, effective payloads, linkers, and conjugation methods for antibody-drug conjugates (ADCs), there is structural diversity and complexity. Moreover, ADCs cannot simply be equated to a combination of antibody drugs and effective payloads, as there are numerous challenges in clinical development, including the complexity of pharmacokinetics, insufficient tumor targeting, … Read more